Intermittent administration of immune activators such as interlukin-2 (IL-2) in combination with highly-active anti- retroviral therapy (HAART) is considered to be an effective strategy for long-term control of HIV replication in vivo. This talk focusses on the design and simulation of a deterministic model that enable the assessment of therapeutic strategies of HIV. The model, which monitors the temporal dynamics of HIV, uninfected CD4+ T cells, CD8+ T cells, productively-infected and latently-infected CD4+ T cells, shows that current therapeutic strategies (including intermittent HAART and IL-2) are insufficient in eradicating HIV. It, however, suggests that eradication is feasible if an uninterrupted HAART and IL-2 therapy is combined with an agent (such as a putative anti-HIV vaccine) that can increase the proliferation of HIV-specific CD4+ and CD8+ T cells as well as the differentiation of CD8+ T cells into anti-HIV cytotoxic T lympocytes.